PCRX Stock: Price, Earnings History and SEC Filings
Pacira BioSciences, Inc. (PCRX) last traded at $36.39, up 0.00% on the latest session and up 45.3% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.44 against an analyst estimate of $0.27, a beat of 63.0%.
$36.39 +0.00%
1 month+45.27%
52-week high$36.67
52-week low$18.80
Volume737,238
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
PCRX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $0.44 | $0.27 | +62.96% |
| Mar 2026 | Apr 30, 2026 | $0.34 | $0.33 | +3.03% |
| Dec 2025 | Feb 26, 2026 | $0.32 | $0.60 | -46.67% |
| Sep 2025 | Nov 6, 2025 | $0.46 | $0.42 | +9.52% |
PCRX beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for PCRX
SEC filing data is not available right now. You can search for PCRX on SEC EDGAR.
PCRX news
- PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its ShareholdersOct 31, 2026 · financialcontent.com
- Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.Oct 30, 2026 · finance.yahoo.com
- Pacira BioSciences (PCRX) Reports Next Week: Wall Street Expects Earnings GrowthOct 29, 2026 · finance.yahoo.com
- IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover WaveOct 27, 2026 · stocktwits.com
- Pacira BioSciences (PCRX) Stock Gets Fair Value Boost After Viatris Deal FramingOct 23, 2026 · finance.yahoo.com
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. (PCRX) is a US-listed public company on Nasdaq.